Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Activating mutations in FLT3 (FMS-like tyrosine kinase 3) are common in acute myeloid leukemia (AML).
• FLT3 mutations, including internal tandem duplications (ITD) and D835 point mutations, drive AML pathogenesis.
• Resistance mutations, particularly at D835, limit the efficacy of current FLT3 inhibitors.

Purpose of the Study:

• To evaluate the efficacy of crenolanib, a next-generation FLT3 tyrosine kinase inhibitor (TKI).
• To compare crenolanib's activity against FLT3/ITD and FLT3/D835 mutants with existing TKIs.
• To assess crenolanib's safety profile, including c-Kit inhibition and myelosuppression.

Main Methods:

• Testing crenolanib against a panel of D835 mutant cell lines and primary patient blasts.
• Comparing cytotoxic effects with quizartinib and sorafenib.
• Evaluating c-Kit inhibition and effects on erythroid progenitor cell growth.
• Analyzing correlative data from an ongoing clinical trial.

Main Results:

• Crenolanib demonstrated superior cytotoxic effects against D835 mutant AML cells compared to quizartinib and sorafenib.
• Crenolanib showed reduced inhibition of c-Kit and less disruption of erythroid progenitor growth than quizartinib.
• Clinical trial data indicated sufficient in vivo drug levels to inhibit FLT3 mutants in AML patients.

Conclusions:

• Crenolanib is a potent and selective FLT3 TKI with activity against common and resistance mutations.
• Its favorable safety profile suggests potential for reduced myelosuppression.
• Crenolanib represents a promising next-generation therapeutic option for FLT3-mutated AML.